TAF1L

Summary

TAF1L (TATA-box binding protein associated factor 1 like, HGNC:18056) is a protein-coding gene on chromosome 9p21.1, encoding Transcription initiation factor TFIID subunit 1-like (Q8IZX4). May act as a functional substitute for TAF1/TAFII250 during male meiosis, when sex chromosomes are transcriptionally silenced.

This locus is intronless, and apparently arose in the primate lineage from retrotransposition of the transcript from the multi-exon TAF1 locus on the X chromosome. The gene is expressed in male germ cells, and the product has been shown to function interchangeably with the TAF1 product.

Source: NCBI Gene 138474 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 240 total
• Druggable target: yes — 2 molecules with ChEMBL bioactivity
• Cancer driver (intOGen): loss-of-function (tumor-suppressor-like) across 1 cancer types
• MANE Select transcript: NM_153809

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18056
Approved symbol	TAF1L
Name	TATA-box binding protein associated factor 1 like
Location	9p21.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000122728
Ensembl biotype	protein_coding
OMIM	607798
Entrez	138474

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000242310

RefSeq mRNA: 1 — MANE Select: NM_153809 NM_153809

CCDS: CCDS35003

Canonical transcript exons

ENST00000242310 — 1 exons

Exon	Start	End
ENSE00003680431	32629454	32635669

Expression profiles

Bgee: expression breadth broad, 14 present calls, max score 76.67.

Top tissues by expression

204 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
superficial temporal artery	UBERON:0001614	76.67	silver quality
mucosa of paranasal sinus	UBERON:0005030	76.35	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	75.94	gold quality
germinal epithelium of ovary	UBERON:0001304	75.25	gold quality
lower lobe of lung	UBERON:0008949	68.08	silver quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	67.69	gold quality
cartilage tissue	UBERON:0002418	67.27	gold quality
trabecular bone tissue	UBERON:0002483	67.01	gold quality
secondary oocyte	CL:0000655	66.05	gold quality
biceps brachii	UBERON:0001507	65.58	gold quality
oral cavity	UBERON:0000167	64.33	gold quality
corpus epididymis	UBERON:0004359	63.54	silver quality
cauda epididymis	UBERON:0004360	63.47	silver quality
jejunal mucosa	UBERON:0000399	63.36	gold quality
caput epididymis	UBERON:0004358	63.09	silver quality
Brodmann (1909) area 46	UBERON:0006483	62.87	gold quality
sperm	CL:0000019	62.54	silver quality
ventral tegmental area	UBERON:0002691	62.49	gold quality
saphenous vein	UBERON:0007318	61.43	gold quality
pericardium	UBERON:0002407	61.29	silver quality
mucosa of sigmoid colon	UBERON:0004993	61.22	gold quality
epithelium of nasopharynx	UBERON:0001951	61.16	gold quality
nipple	UBERON:0002030	61.12	silver quality
quadriceps femoris	UBERON:0001377	61.00	gold quality
pigmented layer of retina	UBERON:0001782	60.95	silver quality
vastus lateralis	UBERON:0001379	60.92	gold quality
thymus	UBERON:0002370	60.83	silver quality
gingival epithelium	UBERON:0001949	60.75	gold quality
layer of synovial tissue	UBERON:0007616	60.72	silver quality
pons	UBERON:0000988	60.63	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.22

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): TP53

miRNA regulators (miRDB)

23 targeting TAF1L, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-512-3P	99.97	67.35	1049
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-548AZ-5P	99.83	69.94	3230
HSA-MIR-548T-5P	99.83	69.91	3220
HSA-MIR-143-3P	99.49	69.05	1457
HSA-MIR-4770	99.49	69.09	1451
HSA-MIR-519D-5P	99.41	69.30	2057
HSA-MIR-6088	99.29	68.45	1284
HSA-MIR-6504-3P	99.17	69.31	2891
HSA-MIR-4711-3P	98.97	66.87	1020
HSA-MIR-4700-5P	98.63	67.43	1915
HSA-MIR-4691-5P	98.41	66.77	1343
HSA-MIR-6792-3P	98.41	66.86	1359
HSA-MIR-4450	98.26	68.35	725
HSA-MIR-12126	98.09	64.82	637
HSA-MIR-4469	97.93	65.81	1319
HSA-MIR-8089	97.74	66.21	1698
HSA-MIR-4667-5P	97.61	66.67	1683
HSA-MIR-6849-3P	97.25	64.57	1371
HSA-MIR-3152-5P	96.98	66.88	819
HSA-MIR-1228-5P	93.60	63.91	91

Literature-anchored findings (GeneRIF, showing 3)

• Arose by retroposition of a processed TAF(II)250 mRNA during primate evolution, replaces its function only in male meiosis. (PMID:12217962)
• TAF1 and TAF1L genes harbored not only somatic mutations but also mutational ITH. (PMID:27571988)
• TAF1L promotes development of oral squamous cell carcinoma via decreasing autophagy-dependent apoptosis. (PMID:32174793)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	taf1	ENSDARG00000035330
mus_musculus	Taf1	ENSMUSG00000031314
rattus_norvegicus	Taf1	ENSRNOG00000002565
drosophila_melanogaster	Taf1	FBGN0010355
caenorhabditis_elegans	taf-1	WBGENE00006382

Paralogs (1): TAF1 (ENSG00000147133)

Protein

Protein identifiers

Transcription initiation factor TFIID subunit 1-like — Q8IZX4 (reviewed: Q8IZX4)

Alternative names: TAF(II)210, TBP-associated factor 1-like, TBP-associated factor 210 kDa, Transcription initiation factor TFIID 210 kDa subunit

All UniProt accessions (1): Q8IZX4

UniProt curated annotations — full annotation on UniProt →

Function. May act as a functional substitute for TAF1/TAFII250 during male meiosis, when sex chromosomes are transcriptionally silenced.

Subunit / interactions. Can bind directly to TATA-box binding protein (TBP). Interacts (via bromo domains) with acetylated lysine residues on the N-terminus of histone H1.4, H2A, H2B, H3 and H4 (in vitro).

Subcellular location. Nucleus.

Tissue specificity. Testis specific, expressed apparently in germ cells.

Similarity. Belongs to the TAF1 family.

RefSeq proteins (1): NP_722516* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001487	Bromodomain	Domain
IPR009067	TAF_II_230-bd	Domain
IPR011177	TAF1_animal	Family
IPR018359	Bromodomain_CS	Conserved_site
IPR022591	TAF1_HAT_dom	Domain
IPR036427	Bromodomain-like_sf	Homologous_superfamily
IPR036741	TAFII-230_TBP-bd_sf	Homologous_superfamily
IPR040240	TAF1	Family
IPR041670	Znf-CCHC_6	Domain

Pfam: PF00439, PF09247, PF12157, PF15288

UniProt features (47 total): sequence variant 23, compositionally biased region 7, helix 7, region of interest 4, domain 2, turn 2, chain 1, short sequence motif 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
3HMH	X-RAY DIFFRACTION	2.05
5IGL	X-RAY DIFFRACTION	2.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IZX4-F1	63.22	0.27

Function

Pathways and Gene Ontology

Reactome pathways

20 pathways

ID	Pathway
R-HSA-167161	HIV Transcription Initiation
R-HSA-167162	RNA Polymerase II HIV Promoter Escape
R-HSA-167172	Transcription of the HIV genome
R-HSA-674695	RNA Polymerase II Pre-transcription Events
R-HSA-6804756	Regulation of TP53 Activity through Phosphorylation
R-HSA-73776	RNA Polymerase II Promoter Escape
R-HSA-73779	RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
R-HSA-75953	RNA Polymerase II Transcription Initiation
R-HSA-76042	RNA Polymerase II Transcription Initiation And Promoter Clearance
R-HSA-162587	HIV Life Cycle
R-HSA-162599	Late Phase of HIV Life Cycle
R-HSA-162906	HIV Infection
R-HSA-1643685	Disease
R-HSA-212436	Generic Transcription Pathway
R-HSA-3700989	Transcriptional Regulation by TP53
R-HSA-5633007	Regulation of TP53 Activity
R-HSA-5663205	Infectious disease
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)
R-HSA-9824446	Viral Infection Pathways

MSigDB gene sets: 0 (showing top):

GO Biological Process (8): regulation of transcription by RNA polymerase II (GO:0006357), male meiotic nuclear division (GO:0007140), positive regulation of DNA-templated transcription (GO:0045893), RNA polymerase II preinitiation complex assembly (GO:0051123), chromatin organization (GO:0006325), chromatin remodeling (GO:0006338), DNA-templated transcription initiation (GO:0006352), transcription by RNA polymerase II (GO:0006366)

GO Molecular Function (7): DNA binding (GO:0003677), histone acetyltransferase activity (GO:0004402), protein serine/threonine kinase activity (GO:0004674), RNA polymerase II general transcription initiation factor activity (GO:0016251), TBP-class protein binding (GO:0017025), histone reader activity (GO:0140566), protein binding (GO:0005515)

GO Cellular Component (3): nucleoplasm (GO:0005654), transcription factor TFIID complex (GO:0005669), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-13 pathways:

Category	Pathways
RNA Polymerase II Transcription	4
Transcription of the HIV genome	2
RNA Polymerase II Transcription Initiation And Promoter Clearance	2
Late Phase of HIV Life Cycle	1
Regulation of TP53 Activity	1
HIV Infection	1
HIV Life Cycle	1
Viral Infection Pathways	1
Generic Transcription Pathway	1
Transcriptional Regulation by TP53	1
Disease	1
Gene expression (Transcription)	1
Infectious disease	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA-templated transcription	3
regulation of DNA-templated transcription	2
transcription by RNA polymerase II	2
male gamete generation	1
meiotic cell cycle	1
meiotic nuclear division	1
positive regulation of RNA biosynthetic process	1
transcription initiation at RNA polymerase II promoter	1
transcription preinitiation complex assembly	1
cellular component organization	1
chromatin organization	1
RNA biosynthetic process	1
nucleic acid binding	1
protein-lysine-acetyltransferase activity	1
histone modifying activity	1
protein kinase activity	1
general transcription initiation factor activity	1
general transcription initiation factor binding	1
nucleosome	1
histone binding	1
chromatin-protein adaptor activity	1
binding	1
nuclear lumen	1
cellular anatomical structure	1
RNA polymerase II, holoenzyme	1
RNA polymerase II transcription regulator complex	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1108 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TAF1L	TBP	P20226	812
TAF1L	BRDT	Q58F21	596
TAF1L	POLR2A	P24928	559
TAF1L	H4C7	Q99525	522
TAF1L	H4C16	P02304	520
TAF1L	BPTF	Q12830	478
TAF1L	DEFB1	P60022	452
TAF1L	PBRM1	Q86U86	449
TAF1L	TAF12	Q16514	441
TAF1L	BRPF1	P55201	434
TAF1L	TAF7	Q15545	433
TAF1L	TAF5L	O75529	421
TAF1L	TAF7L	Q5H9L4	414
TAF1L	TAF9B	Q9HBM6	408
TAF1L	TAF3	Q5VWG9	407

IntAct

11 interactions, top by confidence:

A	B	Type	Score
TAF1L	Dlg4	psi-mi:“MI:0407”(direct interaction)	0.440
TBP	TAF1L	psi-mi:“MI:0915”(physical association)	0.370
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350
DYRK1A	TEX13D	psi-mi:“MI:0914”(association)	0.350
AURKAIP1	VWA8	psi-mi:“MI:2364”(proximity)	0.270
LHX3	BCL9	psi-mi:“MI:2364”(proximity)	0.270
LHX4	BCL9	psi-mi:“MI:2364”(proximity)	0.270
FLT3	KIF2A	psi-mi:“MI:2364”(proximity)	0.270
PSTPIP1	TAF1L	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (25): TAF1L (Affinity Capture-RNA), TAF1L (Affinity Capture-MS), TAF1L (Proximity Label-MS), TAF1L (Proximity Label-MS), TAF1L (Affinity Capture-MS), TAF1L (Affinity Capture-MS), TBP (Two-hybrid), TAF1L (Proximity Label-MS), TAF1L (Proximity Label-MS), TAF1L (Affinity Capture-MS), TAF1L (Proximity Label-MS), TAF1L (Affinity Capture-MS), MRPL20 (Affinity Capture-MS), TAF1L (Affinity Capture-MS), TAF1L (Negative Genetic)

ESM2 similar proteins: A2BD83, F4HQA1, F4HRV8, F4ICK8, O43290, P21675, P35269, Q04870, Q13435, Q15545, Q1RMR0, Q2HJG8, Q2KJ14, Q3THK3, Q3UJB0, Q4R5A5, Q4U0S5, Q4V886, Q52KV5, Q53F19, Q5EA53, Q5HZB6, Q5R4D6, Q5R7L9, Q5RAX0, Q5XIW8, Q5XJE5, Q5ZHP7, Q5ZIH9, Q5ZIM6, Q5ZM19, Q641X2, Q6AY96, Q6NYV9, Q6P2Y1, Q6R1L1, Q80UV9, Q811X5, Q8BZR9, Q8CFC7

Diamond homologs: A0A0R4IXF6, A0A7U2QYM2, A2AHJ4, A2AUY4, A2BIL7, B2RRD7, B7ZS37, D4A7T3, E9Q2Z1, F1QW93, F1R5H6, F7DRV9, G5E8P1, O15164, O60885, O74350, O88379, O88665, O95696, P13709, P21675, P25440, P35817, P51123, P53236, P54816, P55201, P87152, Q02206, Q03330, Q07442, Q08D75, Q09948, Q12830, Q15059, Q1LUC3, Q23590, Q32S26, Q338B9, Q4R8Y1

SIGNOR signaling

0 interactions.

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: loss-of-function (tumor-suppressor-like) across 1 cancer types — COADREAD.

Clinical variants and AI predictions

ClinVar

240 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	228
Likely benign	10
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

12 predictions. Top by Δscore:

Variant	Effect	Δscore
9:32633814:T:C	donor_gain	0.7300
9:32633813:A:AC	donor_gain	0.5500
9:32633813:AT:A	donor_gain	0.4800
9:32635500:T:TA	donor_gain	0.4500
9:32634708:T:TA	donor_gain	0.4300
9:32635482:C:CT	donor_gain	0.4300
9:32635483:C:CT	donor_gain	0.4000
9:32635398:CA:C	donor_gain	0.3300
9:32634693:T:TA	donor_gain	0.2900
9:32635487:T:TA	donor_gain	0.2600
9:32634776:C:A	donor_gain	0.2500
9:32635076:AT:A	donor_gain	0.2200

AlphaMissense

12128 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:32634085:A:G	W499R	1.000
9:32634085:A:T	W499R	1.000
9:32634502:A:G	W360R	1.000
9:32634502:A:T	W360R	1.000
9:32632382:A:C	F1066L	0.999
9:32632382:A:T	F1066L	0.999
9:32632384:A:G	F1066L	0.999
9:32632454:C:A	W1042C	0.999
9:32632454:C:G	W1042C	0.999
9:32634083:C:A	W499C	0.999
9:32634083:C:G	W499C	0.999
9:32634500:C:A	W360C	0.999
9:32634500:C:G	W360C	0.999
9:32631297:A:T	V1428D	0.998
9:32631732:C:G	C1283S	0.998
9:32631733:A:G	C1283R	0.998
9:32631733:A:T	C1283S	0.998
9:32632383:A:C	F1066C	0.998
9:32632456:A:G	W1042R	0.998
9:32632456:A:T	W1042R	0.998
9:32632503:A:G	L1026P	0.998
9:32632539:A:G	L1014P	0.998
9:32633413:A:C	Y723D	0.998
9:32634084:C:G	W499S	0.998
9:32634492:C:T	G363E	0.998
9:32631155:A:C	S1475R	0.997
9:32631155:A:T	S1475R	0.997
9:32631157:T:G	S1475R	0.997
9:32631243:A:G	L1446P	0.997
9:32631688:A:G	C1298R	0.997

dbSNP variants (sampled 300 via entrez): RS1000372360 (9:32636499 G>A), RS1001340895 (9:32635660 A>G), RS1001421235 (9:32636254 T>C), RS1001516658 (9:32629076 T>A), RS1001893771 (9:32635099 G>A), RS1002342546 (9:32629171 G>A), RS1002397317 (9:32636771 A>C,G), RS1002579352 (9:32637347 C>G,T), RS1002698405 (9:32629428 G>A), RS1003568051 (9:32636019 T>G), RS1004216132 (9:32636844 A>G), RS1004769376 (9:32635824 C>T), RS1005811272 (9:32629510 A>G), RS1006489237 (9:32637275 A>G,T), RS1006930119 (9:32634778 C>T)

Disease associations

OMIM: gene MIM:607798 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST001547_8	Immune response to anthrax vaccine	8.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004645	response to vaccine

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3108641 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 595 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL4078100	AZD-5153	1	591
CHEMBL5426285	5-(6-BENZOTHIAZOLYLMETHYLENE)-3,5-DIHYDRO-2-(((1S)-1-(METHOXYMETHYL)-3-METHYLBUTYL)AMINO)-4H-IMIDAZOL-4-ONE, (5Z)-	1	4

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — TAF1 family

ChEMBL bioactivities

21 potent at pChembl≥5 of 26 total, top 17 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.22	IC50	0.6	nM	5-(6-BENZOTHIAZOLYLMETHYLENE)-3,5-DIHYDRO-2-(((1S)-1-(METHOXYMETHYL)-3-METHYLBUTYL)AMINO)-4H-IMIDAZOL-4-ONE, (5Z)-
8.30	Kd	5	nM	CHEMBL4463538
7.60	Kd	25.12	nM	CHEMBL4449894
7.36	Kd	44	nM	CHEMBL4648912
6.97	IC50	106	nM	CHEMBL4086276
6.91	IC50	124	nM	CHEMBL5190023
6.90	Ki	125.9	nM	CHEMBL3590408
6.63	Kd	234.7	nM	CHEMBL4086276
6.40	Kd	398.1	nM	GSK789
6.21	Kd	610	nM	CHEMBL5270178
6.00	Kd	1000	nM	CHEMBL3823478
5.89	Kd	1300	nM	CHEMBL3356559
5.70	Kd	1995	nM	GSK973
5.60	Ki	2512	nM	AZD-5153
5.50	Kd	3190	nM	CHEMBL3739699
5.50	Kd	3200	nM	CHEMBL4208820
5.50	Kd	3200	nM	CHEMBL3739699

PubChem BioAssay actives

16 with measured affinity, of 123 total; 14 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(5Z)-5-(1,3-benzothiazol-6-ylmethylidene)-2-[(2R)-1-methoxy-4-methylpentan-2-yl]iminoimidazolidin-4-one	2024511: Inhibition of human TAF1L assessed as remaining activity by eurofins-cerep kinase profiler analysis	ic50	0.0006	uM
6-but-3-enyl-4-[1-methyl-6-(morpholine-4-carbonyl)benzimidazol-4-yl]-1H-pyrrolo[2,3-c]pyridin-7-one	1513943: Binding affinity to recombinant human full length DNA-tagged TAF1L bromodomain 2 (1523 to 1654 residues) expressed in bacterial expression system by bromoscan assay	kd	0.0050	uM
N-[4-bromo-3-[(3S)-3-methylpyrrolidin-1-yl]sulfonylphenyl]-2-[(4S)-4-cyclopropyl-4-methyl-2,5-dioxoimidazolidin-1-yl]acetamide	1561913: Binding affinity to human partial length TAF1L bromodomain 2 (Q1523 to D1654 residues) expressed in bacterial expression system by BROMOscan assay	kd	0.0251	uM
N-[1-(1,1-dipyridin-2-ylethyl)-6-(1-methyl-7-oxo-6H-pyrrolo[2,3-c]pyridin-3-yl)indol-4-yl]ethanesulfonamide	1652267: Binding affinity to human partial length TAF1L bromodomain 2 (Q1523 to D1654 residues) expressed in bacterial expression system by BROMOscan assay	kd	0.0440	uM
6-(3-hydroxypropyl)-2-(1,3,6-trimethyl-2-oxobenzimidazol-5-yl)benzo[de]isoquinoline-1,3-dione	1482420: Inhibition of human GST-tagged TAF1L BD2 (1517 to 1649 residues) expressed in Escherichia coli BL21 (DE3)-R3-pRARE2 preincubated for 15 mins followed by addition of C-terminal biotinylated synthetic K5,8,12,16 tetra-acetylated histone H4 (1 to 20 residues) peptide as substrate measured after 1 hr by TR-FRET assay	ic50	0.1060	uM
cis-(1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide	1856719: Inhibition of TAF1L (unknown origin)	ic50	0.1240	uM
8-[[(3R,4R)-3-[(1,1-dioxothian-4-yl)methoxy]-1-methylpiperidin-4-yl]amino]-3-methyl-5-(5-methyl-3-pyridinyl)-1H-1,7-naphthyridin-2-one	1234384: Binding affinity to TAF1L (unknown origin) by BROMOscan panel based assay	ki	0.1259	uM
(3R,4R)-N-cyclohexyl-4-[[5-(furan-2-yl)-3-methyl-2-oxo-1H-1,7-naphthyridin-8-yl]amino]-1-methylpiperidine-3-carboxamide	1721403: Binding affinity to human partial length TAF1L bromodomain 2 (Q1523 to D1654 residues) expressed in bacterial expression system by BROMOscan assay	kd	0.3981	uM
6-[(E)-but-2-enyl]-4-[4-(morpholine-4-carbonyl)phenyl]-1H-pyrrolo[2,3-c]pyridin-7-one	1958312: Binding affinity to human partial length TAF1L bromodomain 2 (Q1523 to D1654 residues) expressed in bacterial expression system by BROMOscan assay	kd	0.6100	uM
4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-2,7-naphthyridin-1-one	2191055: Binding affinity to TAF1L (unknown origin) assessed as dissociation constant by bromoKdselect analysis	kd	1.0000	uM
N-tert-butyl-2-[4-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]imidazo[1,2-a]pyrazin-3-amine	1169321: Binding affinity to TAF1L (unknown origin) by bromodomain displacement assay	kd	1.3000	uM
(3R)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl]phenoxy]ethyl]-1,3-dimethylpiperazin-2-one	1632431: Inhibition of human TAF1L bromodomain 2 expressed in bacterial expression system	ki	2.5119	uM
1-[1-(2-methylsulfonylphenyl)-7-propoxyindolizin-3-yl]ethanone	1279763: Binding affinity to biotinylated C-terminal Avi/His-TEV-fused TAF1L bromodomain-2 (unknown origin) expressed in Escherichia coli by isothermal titration calorimetric analysis	kd	3.1900	uM
5-[8-[5-acetyl-1-(oxan-4-yl)-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-3-yl]isoquinolin-3-yl]-N-methylpyridine-2-carboxamide	1372272: Binding affinity to human partial length TAF1L bromodomain 2 (Q1523 to D1654 residues) expressed in bacterial expression system by BROMOscan assay	kd	3.2000	uM

CTD chemical–gene interactions

9 total (human), top 9 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects cotreatment, decreases methylation	1
sodium arsenite	increases expression	1
CGP 52608	affects binding, increases reaction	1
clothianidin	decreases expression	1
Fulvestrant	decreases methylation, increases methylation, affects cotreatment	1
Arsenic	affects methylation	1
Dronabinol	decreases expression	1
Tunicamycin	increases expression	1
Thapsigargin	increases expression	1

ChEMBL screening assays

94 unique, capped per target: 94 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3111339	Binding	Binding affinity to TAF1L bromodomain-2 (unknown origin) assessed as change in melting temperature at 10 uM by differential scanning fluorimetric analysis	[1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains. — J Med Chem

Cellosaurus cell lines

2 cell lines: 1 transformed cell line, 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_KW10	InCELL Hunter HEK 293 TAF1L(2) Bromodomain	Transformed cell line	Female
CVCL_TR48	HAP1 TAF1L (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.